FGFR2 alterations in endometrial carcinoma

FGFR2 alterations in endometrial carcinoma

Item
http://www.wikidata.org/entity/Q59123115
Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsFGF receptors: cancer biology and therapeuticsDevelopment of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Protein domain-level landscape of cancer-type-specific somatic mutations.Endometrial carcinoma: molecular alterations involved in tumor development and progression.Molecular pathology of endometrial carcinoma.Endometrial cancer: redefining the molecular-targeted approach.Endometrial Carcinoma: Specific Targeted Pathways.Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text MiningSafety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.Next-Generation Sequencing.
P2860

FGFR2 alterations in endometrial carcinoma

Item
http://www.wikidata.org/entity/Q59123115
description
scientific article published on 01 July 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2011
@uk
name
FGFR2 alterations in endometrial carcinoma
@en
FGFR2 alterations in endometrial carcinoma
@nl
type
label
FGFR2 alterations in endometrial carcinoma
@en
FGFR2 alterations in endometrial carcinoma
@nl
prefLabel
FGFR2 alterations in endometrial carcinoma
@en
FGFR2 alterations in endometrial carcinoma
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
FGFR2 alterations in endometrial carcinoma
@en
P2093
P2860
P2888
P304
P31
P356
10.1038/MODPATHOL.2011.110
P433
P478
P50
P577
P698